Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Barth

Showing results (361-370 of 380) with videos related to

Pageof 38
Sort By:
Haematologica|November 3, 2009
Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trialsHeinz-Wolfram Bernd, Marita Ziepert, Christoph Thorns, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|October 28, 2025
DKK3 Initially Preserves Acinar Integrity Through MEK-Fos Signaling, but Later Switches to an Oncogenic Role in Pancreatic CancerDharini Srinivasan, Elodie Roger, Lukas Perkhofer, et al.
EMBO Molecular Medicine|February 16, 2022
Compound heterozygous variants in OTULIN are associated with fulminant atypical late-onset ORASJulia Zinngrebe, Barbara Moepps, Thomas Monecke, et al.
Blood|August 26, 2010
Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHLGerman Ott, Marita Ziepert, Wolfram Klapper, et al.
Science Advances|September 3, 2025
Selective targeting of TBXT with DARPins identifies regulatory networks and therapeutic vulnerabilities in chordomaCharles S Umbaugh, Marie Groth, Cihan Erkut, et al.
Infection Control and Hospital Epidemiology|October 5, 2018
Whole-genome sequencing for methicillin-resistant Staphylococcus aureus (MRSA) outbreak investigation in a neonatal intensive care unitTheresa Madigan, Scott A Cunningham, Robin Patel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2017
Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study GroupAnnette M Staiger, Marita Ziepert, Heike Horn, et al.
Leukemia|February 18, 2015
Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphomaH Horn, M Ziepert, M Wartenberg, et al.
Journal of Medicinal Chemistry|January 5, 1996
Discovery of the hemifumarate and (alpha-L-alanyloxy)methyl ether as prodrugs of an antirheumatic oxindole: prodrugs for the enolic OH groupR P Robinson, L A Reiter, W E Barth, et al.
Journal of Medicinal Chemistry|March 29, 2018
Correction to Discovery of the Hemifumarate and (α-l-Alanyloxy)methyl Ether as Prodrugs of an Antirheumatic Oxindole: Prodrugs for the Enolic OH GroupRalph P Robinson, Lawrence A Reiter, Wayne E Barth, et al.
Pageof 38

Showing results (361-370 of 380) with videos related to

Sort By:
Pageof 38
Haematologica|November 3, 2009
Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trialsHeinz-Wolfram Bernd, Marita Ziepert, Christoph Thorns, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|October 28, 2025
DKK3 Initially Preserves Acinar Integrity Through MEK-Fos Signaling, but Later Switches to an Oncogenic Role in Pancreatic CancerDharini Srinivasan, Elodie Roger, Lukas Perkhofer, et al.
EMBO Molecular Medicine|February 16, 2022
Compound heterozygous variants in OTULIN are associated with fulminant atypical late-onset ORASJulia Zinngrebe, Barbara Moepps, Thomas Monecke, et al.
Blood|August 26, 2010
Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHLGerman Ott, Marita Ziepert, Wolfram Klapper, et al.
Science Advances|September 3, 2025
Selective targeting of TBXT with DARPins identifies regulatory networks and therapeutic vulnerabilities in chordomaCharles S Umbaugh, Marie Groth, Cihan Erkut, et al.
Infection Control and Hospital Epidemiology|October 5, 2018
Whole-genome sequencing for methicillin-resistant Staphylococcus aureus (MRSA) outbreak investigation in a neonatal intensive care unitTheresa Madigan, Scott A Cunningham, Robin Patel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2017
Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study GroupAnnette M Staiger, Marita Ziepert, Heike Horn, et al.
Leukemia|February 18, 2015
Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphomaH Horn, M Ziepert, M Wartenberg, et al.
Journal of Medicinal Chemistry|January 5, 1996
Discovery of the hemifumarate and (alpha-L-alanyloxy)methyl ether as prodrugs of an antirheumatic oxindole: prodrugs for the enolic OH groupR P Robinson, L A Reiter, W E Barth, et al.
Journal of Medicinal Chemistry|March 29, 2018
Correction to Discovery of the Hemifumarate and (α-l-Alanyloxy)methyl Ether as Prodrugs of an Antirheumatic Oxindole: Prodrugs for the Enolic OH GroupRalph P Robinson, Lawrence A Reiter, Wayne E Barth, et al.
Pageof 38